Theradaptive, Inc
Theradaptive is a platform company focused on delivering targeted, localized therapeutic proteins using a proprietary technology to bind bioactive molecules to implantable substrates for use in spine, dental, and oncology initially. Founded in 2016 and headquartered in Maryland, U.S., Theradaptive is a venture-backed biopharmaceutical company with the central goal of leveraging their therapeutic delivery platform to deliver proteins to where they are needed in the body. Theradaptive is led by CEO Luis Alvarez Ph.D, and its innovative technologies, enabling vascular, soft tissue and orthopedic repair originate in M.I.T., where Luis attended university. Using a proprietary method, Theradaptive can convert any recombinant protein into a variant that can be “painted” onto medical devices or other substrates. This makes it possible to coat implants, devices, and injectable carriers to deliver a therapeutic directly to where it is needed most, for localized, directed, low-dose applications. The company’s first therapeutic area is in orthopedics, where it is currently in preclinical development for dental and spine applications, but has also begun expanding its technology to treat cancer.
